Bristol Myers Squibb (CELG-RI) Current Assets (2009 - 2026)

Bristol Myers Squibb has disclosed Current Assets across 18 years of filings, most recently posting $27.2 billion for Q1 2026.

• In Q1 2026, Current Assets fell 11.61% year-over-year to $27.2 billion; the TTM figure through Mar 2026 stood at $27.2 billion (down 11.61% YoY), while the FY2025 annual figure was $29.4 billion, down 1.31% from the prior year.
• Current Assets slipped to $27.2 billion in Q1 2026, from $29.4 billion in the prior quarter.
• Over the last five years, Current Assets for CELG-RI reached as high as $35.6 billion in Q3 2025 and fell as low as $26.8 billion in Q3 2022.
• The 5-year median for Current Assets is $28.7 billion (2024), against an average of $29.3 billion.
• Annual changes were most pronounced in 2022 — Current Assets decreased 18.01% — and 2025, when it climbed 26.91%.
• A 5-year view of Current Assets shows it stood at $27.3 billion in 2022, then rose by 16.49% to $31.8 billion in 2023, then dropped by 6.26% to $29.8 billion in 2024, then fell by 1.31% to $29.4 billion in 2025, then dropped by 7.42% to $27.2 billion in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $27.2 billion, $29.4 billion, and $35.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.